Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

ALSYMPCA trial: Ra-223 effective and well-tolerated for CRPC with symptomatic bone metastases

Name: ALSYMPCA trial: Ra-223 effective and well-tolerated for CRPC with symptomatic bone metastases
Uploaded: 2014-02-01T00:00:00+00:00
Description: Dr Sten Nilsson from Karolinska University Hospital, Stockholm, Sweden joins ecancer at ASCO GU 2014 to discuss recent data from the phase III ALSYMPCA trial. The discussion includes how radium-223 is an effective treatment against mCRPC and bone metastases.

2014 Genitourinary Cancers Symposium

30 Jan - 1 Feb 2014

Published: 1 Feb 2014

Rating:

Save

Dr Sten Nilsson - Karolinska University Hospital, Stockholm, Sweden

Dr Sten Nilsson from Karolinska University Hospital, Stockholm, Sweden joins ecancer at ASCO GU 2014 to discuss recent data from the phase III ALSYMPCA trial. The discussion includes how radium-223 is an effective treatment against mCRPC and bone metastases.

Related Videos

Prostate cancer

Dr Alison Tree - Institute of Cancer Research, London, UK

22 Jan 2025

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard

15 Sep 2024

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

15 Sep 2024

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

30 Jul 2024

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma

Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA

$Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma ( Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA )$

9 Jul 2024

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

26 Jun 2024

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio

9 Apr 2024

Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer

Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK

$Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer ( Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK )$

17 Feb 2023

ALSYMPCA trial: Ra-223 effective and well-tolerated for CRPC with symptomatic bone metastases

2014 Genitourinary Cancers Symposium

Related Videos

More from ecancer